Highlights Xynomic Pharmaceuticals Holdings, Inc. Nasdaq

Equities

BCACU

VGG1142P1201

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-19.05%

2021	Xu-Nuo Pharma, Inc. acquired the remaining 2% stake in Xynomic Pharmaceuticals Holdings, Inc..	CI
2020	Xynomic Pharmaceuticals Holdings, Inc. Announces Resignation of Richard Peidong Wu as Independent Director and the Chairman of the Audit Committee	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Xu-Nuo Pharma, Inc. acquired the remaining 2% stake in Xynomic Pharmaceuticals Holdings, Inc..	16/06/21	CI
BROOKLINE CAPITAL ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)	04/06/21	AQ
Brookline Capital Acquisition Corp. Completes Closing of $57,500,000 Initial Public Offering	02/02/21	GL
Brookline Capital Acquisition Corp. Announces Pricing of $50,000,000 Initial Public Offering	28/01/21	GL
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	01/06/20	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	14/11/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma	23/09/19	CI
Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial	13/09/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda in Multiple Solid Tumors	30/08/19	CI
Xynomic Research Institute Has Successfully Designed a Series of Potent RET Kinase Inhibitors	16/08/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	15/08/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Approves Application to Conduct Pivotal Phase 3 Trial Using Abexinostat	07/08/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Files Fast-Track Designation Application for Follicular Lymphoma Treatment with the U.S. FDA	01/08/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Receives China Approval to Start 2 Pivotal Lymphoma Clinical Trials	30/07/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Completes Pre-IND Meeting with US FDA for XP-102	12/06/19	CI
Xynomic Pharmaceuticals Holdings, Inc. Doses First Patient in Phase 1/2 Lymphoma Trial	06/06/19	CI
Xynomic Pharmaceuticals, Inc completed the acquisition of Bison Capital Acquisition Corp. in a reverse merger transaction.	14/05/19	CI
China, Spain and Poland Authorities Approves Xynomic Pharmaceuticals, Inc.'s Application	16/03/19	CI
Xynomic Pharma Will Present at ASCO-GU Cancers Symposium, Files 3 INDs for Potentially Pivotal Cancer Trials in China, and Expands R&D Operations	27/12/18	CI
Xynomic Pharmaceuticals, Inc entered into a non-binding letter of intent to acquire Bison Capital Acquisition Corp. in a reverse merger transaction.	11/09/18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Xynomic Pharmaceuticals Holdings, Inc. Nasdaq

Equities

BCACU

VGG1142P1201

Highlights

Filters